CZ253395A3 - Method of controlled activation and degradation of factor vii during purification process - Google Patents

Method of controlled activation and degradation of factor vii during purification process Download PDF

Info

Publication number
CZ253395A3
CZ253395A3 CZ952533A CZ253395A CZ253395A3 CZ 253395 A3 CZ253395 A3 CZ 253395A3 CZ 952533 A CZ952533 A CZ 952533A CZ 253395 A CZ253395 A CZ 253395A CZ 253395 A3 CZ253395 A3 CZ 253395A3
Authority
CZ
Czechia
Prior art keywords
fvii
buffer
nacl
activation
degradation
Prior art date
Application number
CZ952533A
Other languages
Czech (cs)
English (en)
Inventor
Tony Jorgensen
Anders H Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CZ253395A3 publication Critical patent/CZ253395A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Catalysts (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CZ952533A 1993-03-31 1994-03-24 Method of controlled activation and degradation of factor vii during purification process CZ253395A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93382A DK38293D0 (da) 1993-03-31 1993-03-31 Fremstilling af proteiner

Publications (1)

Publication Number Publication Date
CZ253395A3 true CZ253395A3 (en) 1996-01-17

Family

ID=8092871

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ952533A CZ253395A3 (en) 1993-03-31 1994-03-24 Method of controlled activation and degradation of factor vii during purification process

Country Status (16)

Country Link
US (1) US5700914A (en:Method)
EP (1) EP0691984A1 (en:Method)
JP (1) JPH08508264A (en:Method)
CN (1) CN1039231C (en:Method)
AU (1) AU677309B2 (en:Method)
CA (1) CA2159313A1 (en:Method)
CZ (1) CZ253395A3 (en:Method)
DK (1) DK38293D0 (en:Method)
FI (1) FI954649A0 (en:Method)
HU (1) HUT72712A (en:Method)
IL (1) IL109164A0 (en:Method)
NO (1) NO953883L (en:Method)
PL (1) PL310887A1 (en:Method)
TW (1) TW278079B (en:Method)
WO (1) WO1994022905A1 (en:Method)
ZA (1) ZA941956B (en:Method)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de) * 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
CN103641885A (zh) † 1998-05-06 2014-03-19 基因技术股份有限公司 用离子交换层析纯化蛋白质
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
PL370652A1 (en) * 2001-12-21 2005-05-30 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1671410B (zh) * 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
CN1780637A (zh) * 2003-03-18 2006-05-31 诺和诺德医疗保健公司 因子ⅶ多肽类的含水液体药物组合物
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
MXPA06001698A (es) 2003-08-14 2006-05-19 Novo Nordisk Healthcare Ag Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
CN102351953B (zh) 2003-12-01 2017-05-10 诺和诺德医疗保健公司 液体因子vii组合物的病毒过滤
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
WO2006067230A1 (en) * 2004-12-23 2006-06-29 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
US20090047723A1 (en) * 2005-01-14 2009-02-19 Bayer Healthcare Llc Method for purification of factor vii
PT1907540E (pt) * 2005-07-22 2013-02-04 Bayer Healthcare Llc Activação do factor vii em solução
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2007073486A2 (en) * 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
CA2888199C (en) 2012-10-17 2019-06-25 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
US11059857B2 (en) 2016-12-22 2021-07-13 Km Biologics Co., Ltd. Chromatographic method for collecting blood coagulation factor VII with high yield

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Also Published As

Publication number Publication date
CN1039231C (zh) 1998-07-22
FI954649A7 (fi) 1995-09-29
FI954649L (fi) 1995-09-29
NO953883L (no) 1995-11-28
FI954649A0 (fi) 1995-09-29
ZA941956B (en) 1994-09-30
WO1994022905A1 (en) 1994-10-13
HU9502846D0 (en) 1995-12-28
DK38293D0 (da) 1993-03-31
HUT72712A (en) 1996-05-28
US5700914A (en) 1997-12-23
PL310887A1 (en) 1996-01-08
CA2159313A1 (en) 1994-10-13
IL109164A0 (en) 1994-06-24
TW278079B (en:Method) 1996-06-11
JPH08508264A (ja) 1996-09-03
EP0691984A1 (en) 1996-01-17
AU677309B2 (en) 1997-04-17
AU6423994A (en) 1994-10-24
NO953883D0 (no) 1995-09-29
CN1121723A (zh) 1996-05-01

Similar Documents

Publication Publication Date Title
CZ253395A3 (en) Method of controlled activation and degradation of factor vii during purification process
AU740753C (en) Improved methods for processing activated protein C
Stenflo Structure and function of protein C
US20080214462A1 (en) FIX-Mutant Proteins for Hemophilia B Treatment
Josic et al. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C
AU2008209986A1 (en) FVIII-independent FIX-mutant proteins for hemophilia A treatment
PL191778B1 (pl) Analog czynnika X Δ , rekombinowany kwas nukleinowy, wektor, komórka, kompozycje i ich zastosowania oraz sposób wytwarzania kompozycji
US6958322B1 (en) Factor X analog with an improved ability to be activated
Himmelspach et al. Recombinant human factor X: high yield expression and the role of furin in proteolytic maturation in vivo and in vitro
RU2167936C2 (ru) Способ минимизации деградации активированного протеина с (варианты), стабилизированная композиция активированного протеина с
US5510248A (en) Stable recombinant meizothrombin-like polypeptides
AU769144B2 (en) Improved methods for processing activated protein C
AU4409399A (en) Human protein c polypeptide
CZ373799A3 (cs) Zlepšené způsoby zpracování aktivovaného proteinu C
Hung Structural-functional Studies of the Non-enzymatic Domains of Prothrombin
Su Localization of ligand-binding exosites in the catalytic domain of FXIa and determination of the roles of calcium and the heavy chain of FXIa in fix activation by FXIa
EP1557463A1 (en) Improved methods for processing activated protein C
Boskovic Studies of prothrombinase-catalyzed activation of bovine prothrombin.
SK124699A3 (en) Activated vitamin k-dependent blood factor and method for the production thereof
HK1219285A1 (en) Purification method for vitamin k dependent proteins by anion exchange chromatography
HK1219285B (en) Purification method for vitamin k dependent proteins by anion exchange chromatography